Veru details 72-week Phase IIb PLATEAU study aimed at obesity plateau group in accordance with FDA recommendations.
Management Transition: Veru Inc. has shifted to focus solely on drug development in cardiometabolic and inflammatory diseases, highlighted by the introduction of enobosarm and sabizabulin, following the sale of its FC2 Female Condom business.
Clinical Trial Updates: The completion of the Phase IIb QUALITY trial showed promising results for enobosarm in preserving lean mass and enhancing fat loss when combined with GLP-1 receptor agonists, leading to the launch of a new 72-week Phase IIb PLATEAU trial targeting obesity in older patients.
Financial Performance: Veru reported a net loss of $15.7 million for fiscal 2025, with increased R&D expenses, but also completed a public offering that bolstered its cash position to support upcoming trials.
Regulatory and Strategic Outlook: Management expressed confidence in navigating regulatory pathways for enobosarm, emphasizing the importance of clinical results and financial readiness, while acknowledging the need for additional capital to sustain operations beyond the interim analysis of the PLATEAU study.
Get Free Real-Time Notifications for Any Stock
Analyst Views on VERU
About VERU
About the author
Veru details 72-week Phase IIb PLATEAU study aimed at obesity plateau group in accordance with FDA recommendations.
Management Transition: Veru Inc. has shifted to focus solely on drug development in cardiometabolic and inflammatory diseases, highlighted by the introduction of enobosarm and sabizabulin, following the sale of its FC2 Female Condom business.
Clinical Trial Updates: The completion of the Phase IIb QUALITY trial showed promising results for enobosarm in preserving lean mass and enhancing fat loss when combined with GLP-1 receptor agonists, leading to the launch of a new 72-week Phase IIb PLATEAU trial targeting obesity in older patients.
Financial Performance: Veru reported a net loss of $15.7 million for fiscal 2025, with increased R&D expenses, but also completed a public offering that bolstered its cash position to support upcoming trials.
Regulatory and Strategic Outlook: Management expressed confidence in navigating regulatory pathways for enobosarm, emphasizing the importance of clinical results and financial readiness, while acknowledging the need for additional capital to sustain operations beyond the interim analysis of the PLATEAU study.
Key Stocks Reporting Earnings This Week: Micron, FuelCell, Carnival, and Others
Earnings Reports Schedule: This week features earnings reports from various companies, including homebuilders, apparel brands, and tech firms, with notable reports from Micron Technology and Nike.
Key Earnings Dates: Major companies reporting include Navan, Ark Restaurants, and Champions Oncology on Monday; Organigram and Duluth Holdings on Tuesday; and a heavy slate on Wednesday with Jabil, General Mills, and Micron.
Investor Focus: Investors are particularly interested in Micron's performance, with expectations of strong earnings driven by high bandwidth memory sales for AI chips.
End of Week Reports: The week will conclude with Carnival Corp and other companies like Paychex and Conagra Brands reporting before Friday's market open.
